Evaluation of the clinical benefit of permixon® and tamsulosin in severe BPH patients - PERMAL study subset analysis;Evaluation du bénéfice clinique de Permixon® et de la Tamsulosine dans le traitement de l'hypertrophie bénigne de la prostate (HBP) sévère: Analyse d'un sous-groupe de l'étude Permal

Progres en Urologie

Volumn 14, Issue 3, 2004, Pages 326-331

  Debruyne, Frans ^a   Boyle, Peter ^b   Calais Da Silva, Fernando ^c   Gillenwater, Jay G ^d   Hamdy, Freddie C ^e   Perrin, Paul ^f   Teillac, Pierre ^g   Vela Navarrete, Remigio ^h   Raynaud, Jean Pierre ⁱ   Schulman, Claude ^j  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Grp Portugais d'Etud Maladies G   (Portugal)

^d UNIVERSITY OF VIRGINIA   (United States)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j ERASME HOSPITAL   (Belgium)

more..

Author keywords

blockers; BPH; Permixon; Phytotherapy; Serenoa repens; Tamsulosin

Indexed keywords

SABAL EXTRACT; TAMSULOSIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; ASTHENIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; EJACULATION DISORDER; FATIGUE; GASTROINTESTINAL TOXICITY; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PHYTOTHERAPY; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SAMPLE SIZE; SEXUAL BEHAVIOR; URINARY TRACT INFECTION; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANDROGEN ANTAGONISTS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA; SEVERITY OF ILLNESS INDEX; SULFONAMIDES;

EID: 4143072518     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. HOLTGREWE H.L. : Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology, 1998 ; 51 : 1-7.
2. OESTERLING J.E. : Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N. Engl. J. Med., 1995 ; 332 : 99-109.
3. BUCK A.C. : Phytotherapy for the prostate. Br. J. Urol., 1996 ; 78 : 325-336.
4. WILT T.J., ISHANI A., STARK G., MACDONALD R., LAU J., MULROW C. : Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998 ; 280 : 1604-1609.
5. LOWE F.C., FAGELMAN E. : Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology, 1999 ; 53 : 671-678.
6. CHACON A., MONGA M. : Medical management of benign prostatic hyperplasia. Geriatr. Nephrol. Urol., 1999 ; 9 : 39-48.
7. CLIFFORD G.M., FARMER R.D. : Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur. Urol., 2000 ; 38 : 2-19.
8. CHAMPAULT G., PATEL J.C., BONNARD A.M. : A double-blind trial of an extract of the plant Serenoa Repens in benign prostatic hypertrophy. Br. J. Clin. Pharmacol., 1984 ; 18 : 461-462.
9. TASCA A., BARULLI M., CAVAZZANA A., ZATTONI F., ARTIBANI W., PAGANO F. : Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo. Minerva Urol. Nephrol., 1985 ; 37 : 87-91.
10. CUKIER J., DUCASSOU J., LE GUILLOU M., ET AL. : Permixon® versus placebo: results of a multicentre study. CR Ther. Pharmacol. Clin., 1985 ; 4: 15-21.
11. DESCOTES J.L., RAMBEAUD J.J., DESCHASEAUX P., FAURE G. : Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin. Drug Invest., 1995 ; 9 : 291-297.
12. BOYLE P., ROBERTSON C., LOWE F., ROEHRBORN C. : Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology, 2000 ; 55 : 533-539.
13. CARRARO J.C., RAYNAUD J.P., KOCH G., ET AL. : Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia : a randomized international study of 1,098 patients. Prostate 1996 ; 29 : 231-240.
14. DEBRUYNE F., KOCH G., BOYLE P., CALAIS DA SILVA F., GILLENWATER J.G., HAMDY F.C., PERRIN P., TEILLAC P., VELA-NAVARRETE R., RAYNAUD J.P. FOR THE MEMBERS OF THE PERMAL STUDY: Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. European Urology, 2002 ; 41 : 497-507.
15. SAW PALMETTO. Rockville, Md. : Pharmacopeial Convention, 2002.
16. GERBER G.S. : Saw palmetto for the treatment of men with lower urinary tract symptoms. J. Urol., 2000 ; 163 : 1408-1412.
17. BARRY M.J., FOWLER F.J., O'LEARY MP, ET AL. : The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol., 1992 ; 148 : 1549-1557.
18. WITJES W.P., DE LA ROSETTE J.J., ZERBIB M., ET AL. : Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flow. Eur. Urol., 1998 ; 33 : 54-63.
19. MARQUIS P., MARREL A. : Reproducibility and clinical concurrent validity of the MSF-4: A four item male sexual function questionnaire for patients with benign prostatic hyperplasia. Value in Health, 2001 ; 4 : 335-343.
20. TERRIS M.K., STAMEY T.A. : Determination of prostate volume by transrectal ultrasound. J. Urol., 1991 ; 145 : 984-987.
21. DENIS L., GRIFFITHS S., KHOURY A.T.K., ET AL. : Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Paris, July 2-5, 1997 : 439-491.
22. LEPOR H. : Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998 ; 51 : 901-906.
23. BROOKS S.K. : Effect of tamsulosin on AUA symptom score and BPH impact index as a function of symptom severity in patients with benign prostatic hyperplasia. J. Urol., 1999 ; 161 Suppl. : 267.
24. DE MEY C. : al-Blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials ? Eur. Urol., 2000 ; 38 : 25-39.
25. SCHULMAN C.C., CORTVRIEND J., JONAS U., LOCK T.M., VAAGE S., SPEAKMAN MJ. : Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur. Urol., 1999 ; 36 : 609-620.
26. VELTRI R.W., MARKS L.S., MILLER M.C. ET AL. : Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: Evidence for a possible molecular mechanism. Urology, 2002 ; 60 : 617-622.